期刊文献+

尾加压素预处理对大鼠心脏缺血再灌注损伤的影响 被引量:4

Effects of human urotensin II on ischemia/reperfusion injury in isolated perfused rat hearts
下载PDF
导出
摘要 目的 :探讨尾加压素 (UII)预处理对于离体灌流大鼠心脏缺血再灌注 (I/R)损伤的影响。方法 :在离体灌流的SD大鼠心脏I/R模型上 ,以UII预灌注心脏 ,采用MFLLab2 0 0心功能软件监测心功能 ,以试剂盒测定心肌细胞ATP、总钙、丙二醛含量和乳酸脱氢酶 (LDH)漏出 ,并观察其对于冠脉流出量 (CPF)的影响。结果 :UII预处理组与单纯I/R组比较 ,冠脉流出液中LDH低 2 8% [(78 3± 18 1)U/Lvs (10 9 3± 2 3 9)U/L ,P <0 0 5 ],心肌组织MDA和钙含量分别低 2 4 %和 2 7% (P <0 0 5 ) ;ATP含量高 73% (P <0 0 5 )。与I/R组比较 ,UII预处理组CPF高 4 2 % [(5 4± 0 7)mL/minvs (3 8± 0 8)mL/min ,P <0 0 5 ],LVEDP低 2 0 % (P <0 0 5 ) ,±dp/dtmax分别高 2 5 %和 4 5 % (P <0 0 5 ) ;冠脉流出液中NO-2 /NO-3 含量高 6 3% (P <0 0 5 )。结论 :UII预处理可以减轻离体灌注大鼠心脏I/R所造成的损伤 ,其机制与NO介导的冠脉扩张效应有关。 AIM: To investigate the effects of human urotensin II (hUII) on ischemia/reperfusion (I/R) injury in isolated rat hearts. METHODS: In the ischemia/reperfusion (I/R) model of isolated perfused rat hearts,the effects of hUII pretreatment on cardiac function was monitored with cardiac function software of MFL Lab200. ATP,total calcium,and malondialdehyde (MDA) content in myocardium were detected. The coronary perfusion flow (CPF) and lactate dehydrogenase (LDH) activity in coronary effluent were measured during reperfusion. RESULTS: In the hUII pretreated group,the release of LDH from myocardium was lower [(78.3±18.1)U/L] than I/R group [(109.3±23.9) U/L,P< 0.05],with decreased contents of MDA and calcium in myocardium (decreased by 24% and 27%,respectively,P< 0.05) and an increased myocardial ATP content [(3.8±0.4)μmol/g dw vs (2.2±0.4)μmol/g dw,P< 0.05)]. At the same time,hUII pretreatment increased CPF [(5.4±0.7) mL/min vs (3.8±0.8) mL/min in I/R group,P< 0.05],reduced left ventricular end-diastolic pressure (LVEDP) by 20% ( P< 0.05) with increased±d p /d t max [(217±38) kPa/s and (119±18) kPa/s vs (173±29) kPa/s and (82±25) kPa/s in I/R groups,respectively,P< 0.05]. hUII pretreatment also increased natrite/natrate (NO -_2/NO -_3) content in coronary effluent [(52.2±12.0)μmol/L vs (32.1±10.2)μmol/L in I/R group,P< 0.05)]. CONCLUSION: hUII pretreatment attenuated I/R injury in isolated perfused rat hearts. The protective mechanism might be associated with NO-mediated coronary vasodilation.
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2003年第11期1456-1458,共3页 Chinese Journal of Pathophysiology
基金 国家自然科学基金资助项目 (30 2 70 5 5 0 ) 北京市自然科学基金资助项目 (70 32 0 4 4 )
关键词 尾加压素 肽类 缺血预处理 心脏缺血再灌注损伤 冠脉扩张效应 Peptides Heart Ischemic preconditioning Reperfusion injury
  • 相关文献

参考文献6

  • 1刘秀华,苏静怡.缺血预处理的研究现状[J].生理科学进展,2001,32(1):83-87. 被引量:23
  • 2张超,谭敦勇.Urotensin-Ⅱ的研究进展[J].中国病理生理杂志,2002,18(8):1002-1006. 被引量:4
  • 3Murry CE, Jennings RB, Reimer KA, et al. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium [J]. Circulation, 1986, 74: 1124- 1136.
  • 4Ames RS, Sarau H, Chambers JK, et al. Hnman urotensin-Ⅱ is a potent vasoconstrictor and agonist for the orphan receptor GPR14 [J]. Nature, 1999, 401:282-286.
  • 5Katano Y, Ishihata A, Aim T, et al, Vasodilator effect of Urotensin Ⅱ, one of the most potent vasocontricting factors on rat coronary arteries [J], Erop J Pharmacol, 2000, 402( 1/2): R5- R7,.
  • 6Gray GA, Jones MR, Sharif I. Human Urotensin Ⅱ increases coronary perfusion pressure in the isolated heart: ostentation by nitric oxide synthase and cycloxygenase inhibition [ J ]. Life Sci, 2001, 69(2) : 175 - 180.

二级参考文献8

共引文献25

同被引文献83

  • 1龚永生,范小芳,吴小脉,高钰琪,胡良冈,毛孙忠.低氧性肺动脉高压大鼠肺组织apelin-APJ系统的变化[J].中国微循环,2006,10(2):119-122. 被引量:7
  • 2李斌,张乐之,周红,何华美.心肌缺血再灌注损伤时细胞核钙含量与核孔复合体通透性的变化[J].中国病理生理杂志,2006,22(5):1010-1014. 被引量:2
  • 3张明,杨鹏麟,龚永生,范小芳,唐疾飞.大鼠心肌缺血预处理及缺血/再灌注损伤模型的改进[J].中国心血管病研究,2006,4(8):617-619. 被引量:9
  • 4Behan DP,Khongsaly O,Ling N,De Souza EB.Urocortin interaction with corticotropin-releasing factor (CRF) binding protein (CRF-BP): a novel mechanism for elevating "free" CRF levels in human brain[J]. Brain Res,1996;725:263-7
  • 5Coulouarn Y, Lihrmann I, Jegou S, Anouar Y, Tostivint H, Beauvillain JC, et al. Cloning of the cDNA encoding the urotensin Ⅱ precursor in frog and human reveals intense expression of the urotensin Ⅱ gene in motoneurons of the spinal cord[J]. Proc Natl Acad Sci U S A,1998;95:15803-8
  • 6Ames RS,Sarau H M,Chambers JK,Willette RN,Aiyar NV,Romanic AM, et al. Human urotensin-Ⅱ is a potent vasoconstrictor and agonist for the orphan receptor GPR14[J].Nature,1999;401:282-6
  • 7Liu Q, Pong SS, Zeng Z, Zhang Q, Howard AD, Williams DL Jr, et al. Identification of urotensin Ⅱ as the endogenous ligand for the orphan G-protein-coupled receptor GPR14[J].Biochem Biophys Res Commun,1999;266:174-8
  • 8Maguire JJ,Kuc RE,Davenport AP.Orphan-receptor ligand human urotensin Ⅱ: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1[J].Br J Pharmacol,2000;131:441-6
  • 9Maclean MR,Alexander D,Stirrat A,Gallagher M,Douglas SA,Ohlstein EH,et al. Contractile responses to human urotensin-Ⅱ in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat[J].Br J Pharmacol,2000;130:201-4
  • 10Hillier C,Berry C,Petrie MC,O'Dwyer PJ, Hamilton C, Brown A, et al.Effects of urotensin Ⅱ in human arteries and veins of varying caliber[J].Circulation,2001;103:1378-81

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部